Press Releases

A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers. The findings, recently published in Cell Reports Medicine, lay the groundwork for further research, including a phase 1 clinical trial of colon cancer patients that is currently underway.

Researchers from the Health Behavior Department at Roswell Park Comprehensive Cancer Center have released a report showing the potential impacts of eliminating the sale of menthol cigarettes in the City of Buffalo. Their analysis was uncovered from data sources including the New York State Cancer Registry, the United State Census Bureau and other recent research on the impact of menthol cigarette bans.

The Chief of Myeloma at Roswell Park Comprehensive Cancer Center will deliver the latest findings of the CARTITUDE-2 clinical trial at the 2024 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), running Feb. 21-24 in San Antonio, Texas.

Roswell Park Comprehensive Cancer Center congratulates Director of Pharmaceutical Chemistry Ravindra Pandey, PhD, for being named a National Academy of Inventors (NAI) Fellow.

Roswell Park Comprehensive Cancer Center is spotlighting our 2024 Super Bowl MVPs — the Most Valuable Pups who are considered the “goodest boys and girls” by patients and staff alike. The cancer center will debut “Tails of Hope,” a local television commercial featuring its therapy dog program, airing in the Buffalo market during the big game on Sunday, February 11.

Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. But clinical studies have shown that drugs called FLT3 inhibitors can extend long-term survival in these patients, especially when given in combination with other treatments. A phase 2 clinical trial led by Roswell Park Comprehensive Cancer Center tested that strategy for treating FLT3-mutated AML, and the encouraging results are newly reported in Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology.

A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer. The work, newly published in Cancer Research, a journal of the American Association for Cancer Research, illustrates potential clinical applications for the novel anticancer agent MRTX1133 and outlines its effect on both the tumor and the surrounding environment.

As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work newly published in Blood Cancer Discovery, a journal of the American Association for Cancer Research, a team of collaborators from Roswell Park Comprehensive Cancer Center and Moffitt Cancer Center report the first strategy for identifying before treatment which patients are at risk for poor outcomes from CAR T-cell therapy — pointing to opportunities to improve the safety and efficacy of this new and fast-growing class of cancer immunotherapies.

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California. Saby George, MD, FACP, Professor of Oncology and Medicine and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center, will deliver an oral abstract summarizing the findings of “A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants with Previously Treated Clear Cell Renal Carcinoma That Is Advanced or Has Spread (CheckMate-67T)” (NCT04810078).